Healthcare Industry News: demineralized bone matrix
News Release - September 29, 2009
Integra LifeSciences Expands Accell Evo3 Product Line3rd Generation demineralized bone matrix Product is Now Available in a New Size for Expanded Surgical Applications
PLAINSBORO, N.J., Sept. 29, 2009 -- (Healthcare Sales & Marketing Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART ) announced today the release of a smaller configuration of the innovative Accell Evo3(R) demineralized bone matrix. Originally introduced as a bone void filler for large orthopedic reconstructive procedures, the new smaller size of Accell Evo3(R) expands the possible application options for the surgeon, particularly in procedures where smaller amounts of demineralized bone matrix are required.
Accell Evo3(R) is an advanced demineralized bone matrix graft material that is composed of the proprietary Accell(R) Bone Matrix, an optimized blend of particulate demineralized bone matrix (DBM), and a unique poloxamer Reverse Phase Medium. The Reverse Phase Medium is a thermo-reversible carrier that thickens at body temperature and is more flowable at room temperature. The carrier imparts exceptional handling and graft containment characteristics for Integra's DBM based products.
The optimized platform of Accell Evo3(R) enables the bone healing process to take advantage of the naturally available bone proteins found in Accell(R) Bone Matrix and DBM. Accell Evo3(R) has been specifically formulated to provide surgeons with excellent intraoperative handling characteristics for proper utilization of the graft material, and is marketed in combination with a new custom designed open bore syringe for easy delivery of the matrix into the operative field.
Bone grafts provide a foundation or scaffold for the patient's body to grow new bone, and can stimulate new bone production and bone fusion. Accell Evo3(R) may be used as a bone graft extender in the spine, extremities and pelvis or as a bone void filler for the extremities and pelvis, and may replace the need to harvest bone graft material from the iliac crest, thus sparing the patient additional surgery and postoperative pain.
"Integra OrthoBiologics is dedicated to advancing patient care by providing the surgeon with a wide range of innovative and high quality bone graft substitutes. We are pleased to provide the advanced Accell Evo3(R) technology in a new configuration to better accommodate the needs of surgeons and their patients," said Bill Weber, Vice President of Integra OrthoBiologics.
The U.S. market size for bone graft substitutes in orthopedic spinal procedures is estimated at $1.4 billion. In 2008, an estimated 880,000 orthopedic procedures were performed in the United States, including over 500,000 spinal fusions. Additional applications are found in orthopedic trauma and reconstructive procedures.
Accell Evo3(R) demineralized bone matrix is sold in the United States through the Integra OrthoBiologics distributor network, which currently distributes Accell(R), DynaGraft(R), and OrthoBlast(R) demineralized bone matrices, as well as the Integra Mozaik(TM) Osteoconductive Scaffold (Strip and Putty). This extensive product line allows the distributor network to provide a broad range of bone graft substitutes to orthopedic surgeons and neurosurgeons.
Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Our products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world. For more information, visit www.Integra-LS.com
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Accell Evo3(R), Integra Mozaik(TM) Osteoconductive Scaffold, Accell(R), Accell TBM(R) (Total Bone Matrix), Accell Connexus(R), DynaGraft(R) and OrthoBlast(R) demineralized bone matrices. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source: Integra LifeSciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.